Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Clinical trials that led to ibrutinib’s approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately studied. We conducted a retrospective analysis of c...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Haematologica
المؤلفون الرئيسيون: Mato, Anthony R., Nabhan, Chadhi, Thompson, Meghan C., Lamanna, Nicole, Brander, Danielle M., Hill, Brian, Howlett, Christina, Skarbnik, Alan, Cheson, Bruce D., Zent, Clive, Pu, Jeffrey, Kiselev, Pavel, Goy, Andre, Claxton, David, Isaac, Krista, Kennard, Kaitlin H., Timlin, Colleen, Landsburg, Daniel, Winter, Allison, Nasta, Sunita D., Bachow, Spencer H., Schuster, Stephen J., Dorsey, Colleen, Svoboda, Jakub, Barr, Paul, Ujjani, Chaitra S.
التنسيق: Artigo
اللغة:Inglês
منشور في: Ferrata Storti Foundation 2018
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927982/
https://ncbi.nlm.nih.gov/pubmed/29419429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.182907
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة